ICBs in combination
ICBs
CERVICAL CANCER
Since the effect of monotherapy for ICBs is often limited, several ICBs in combination are expected to enhance anti-tumor activity (Balstilimab and Zalifrelimab. Balstilimab is an anti-PD-1 monoclonal antibody, and Zalifrelimab is an anti-CTLA-4 monoclonal antibody. A phase II study of Balstilimab and Zalifrelimab in combination as the second-line treatment for advanced cervical cancer had shown its results (